Figure 3.
Figure 3. sHLA-G1 inhibits FGF2-induced corneal angiogenesis in vivo. Neovascularization was assessed 8 days after the insertion of implants containing FGF2 in rabbit corneal pockets, in the presence or absence of sHLA-G1 (5 μg/injection). (A) Representative image of each group (control, PBS subconjunctival injections; sG1, sHLA-G1 subconjunctival injections) at day 8 after FGF2 pellet implantation. (Arrows) Pellet implants. (Arrowhead) Newly formed vessels. The rabbit's eyes were examined under a OPMI-1 FC slit lamp biomicroscope (Carl Zeiss, Berlin, Germany) using a 2.4×/1.6 NA objective. (B) Neovascularization (NV) scores (mean ± SEM) for 8 implant groups. *P < .001, Student t test.

sHLA-G1 inhibits FGF2-induced corneal angiogenesis in vivo. Neovascularization was assessed 8 days after the insertion of implants containing FGF2 in rabbit corneal pockets, in the presence or absence of sHLA-G1 (5 μg/injection). (A) Representative image of each group (control, PBS subconjunctival injections; sG1, sHLA-G1 subconjunctival injections) at day 8 after FGF2 pellet implantation. (Arrows) Pellet implants. (Arrowhead) Newly formed vessels. The rabbit's eyes were examined under a OPMI-1 FC slit lamp biomicroscope (Carl Zeiss, Berlin, Germany) using a 2.4×/1.6 NA objective. (B) Neovascularization (NV) scores (mean ± SEM) for 8 implant groups. *P < .001, Student t test.

Close Modal

or Create an Account

Close Modal
Close Modal